Info all Articles

2012 was an exciting year for the Abramson Cancer Center. We are featuring blogs featured on the Focus On Cancer blog that highlight cancer treatment breakthroughs, coping tips and ideas, education and inspiration. Today, we are highlighting the partnership between the Stand Up 2 Cancer Foundation and Penn Medicine.

The SU2C Dream Team at Penn is actively researching better ways to prevent, diagnose and treat pancreatic cancer. Together, members of the Pancreatic Cancer Dream Team working to translate scientific breakthroughs into new treatment options faster than ever before.

About Stand Up 2 Cancer

Founded in 2008, SU2C has raised more than $180 million for innovative cancer research. Since its inception, SU2C has made grants to seven multi-disciplinary “Dream Teams” of researchers as well as to 26 young innovative scientists who are undertaking potentially high-reward projects to end the reign of cancer as a leading cause of death in the world today.

Eighty-five institutions are currently involved, including Penn Medicine’s Abramson Cancer Center.

The Penn Medicine SU2C Dream Team

As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.

The SU2C Dream Team at Penn is actively researching better ways to prevent, diagnose and treat pancreatic cancer. Together, members of the Pancreatic Cancer Dream Team working to translate scientific breakthroughs into new treatment options faster than ever before. Their research focuses on developing tests using advanced imaging technology to understand pancreatic cancer cells and developing new, personalized pancreatic cancer treatments based on their research.

Members of the Pancreatic Cancer SU2C Dream Team at Penn Medicine

Pancreatic cancer researchers at Penn Medicine are at the forefront of developing new, personalized approaches to pancreatic cancer treatment.

These Penn clinicians and researchers are part of the SU2C Pancreatic Cancer Dream Team.

Chi Van Dang, MD, PhD
Professor of Medicine, Hematology/Oncology
Director, Abramson Cancer Center
Director, Abramson Family Cancer Research Institute

Jeffrey A. Drebin, MD, PhD, FACS
John Rhea Barton Professor of Surgery
Chairman, Department of Surgery

Hank Kung, PhD
Professor of Radiology and Pharmacology
Department of Radiology
Perelman School of Medicine

Peter J. O’Dwyer, MBBCh, MD
Professor of Medicine, Hematology/Oncology
Perelman School of Medicine

Watch Stand Up 2 Cancer and Join the Conversation

Watch Stand Up to Cancer on Friday, September 7 at 8 pm ET, and join Penn Medicine on Twitter as we discuss pancreatic cancer and its treatment at Penn Medicine, and how researchers and clinicians on the SU2C Pancreatic Cancer Dream Team are changing the way cancer is treated today.

Cancer Information From a Reliable Source

Thank you for a fantastic 2012. The Focus On Cancer blog is committed to provide people with cancer and their caregivers educated information from a reliable source, the Abramson Cancer Center at Penn Medicine. Please subscribe to our blog to get updates about new cancer treatments at Penn, credible information from cancer experts at Penn, and inspiration from other people with cancer.